New agreement for an international research collaboration in drug discovery
Published on April 20, 2022
IRIC is pleased to announce the signing of a collaboration agreement between Ono Pharmaceutical Co, Ltd. (“Ono”), one of the largest clinical stage pharmaceutical companies in Japan, Domain Therapeutics S.A. (“Domain”) and the Université de Montréal to discover novel small molecules targeting G protein-coupled receptors (GPCRs) for the treatment of metabolic diseases.
With this agreement, Michel Bouvier’s research team, Director General of IRIC, Professor in the Department of Biochemistry and Molecular Medicine of the Faculty of Medicine of the Université de Montréal and Director of the Molecular Pharmacology Research Unit, will collaborate with Ono and Domain using the bioSens-All® technology, a GPCR-targeted drug discovery platform, as well as their expertise in medicinal chemistry and GPCR pharmacology. The objective of this agreement is to design and optimize innovative small molecules against a GPCR selected as a therapeutic target by Ono and to develop a future drug development program.
“Very early on, we have accumulated a great expertise on GPCR and its pharmacology,” notes Michel Bouvier. “This new alliance makes it possible to establish a strong link between our research team, Domain Therapeutics, a longtime partner, and Ono Pharmaceuticals, our new strategic partner, for the benefit of patients suffering from metabolic disease.”
To read Ono’s press release, click here.